Furthermore, FGFR2-amplified GCs are more likely to be of high tumour grade [30], and of diffuse-type histology [27,31,32], and several studies have associated FGFR2 amplification status with poorer survival outcomes. The gene discussed is FGFR2; the disease is neoplasm.